TAK: 武田薬品工業(株)

TAK News

• 12:38 Novavax's Second-Largest Shareholder Sells $32.6 Million in Stock, Ends Activist Push
• 09:53 Takeda Announces New Data From VERDICT Showing That Treating Adults With Intravenous ENTYVIO To Achieve Corticosteroid-Free Disease Clearance Resulted In Significantly Longer Time To First Ulcerative Colitis-Related Complication, Reducing UC...
• 17:52 Ascentage Pharma Stock Could More Than Double: Analyst
• 07:01 Reported Earlier, Takeda Launches ORZEYFUL In Japan And China As First-In-Class Orexin Agonist For Narcolepsy Type 1, With US Launch Set For Next Month After DEA Scheduling
• 12:13 Takeda Reports TAK-881 Cuts Infusion Volume 50%, Single-Site Infusion Time 42.6% Vs. HyQvia In Phase 2/3 Immunodeficiency Trial
• 19:48 Takeda Remains A Buy, Boosted By Recent Narcolepsy Drug Approval And Robust Pipeline
• 06:52 Takeda Presents Phase 3 Data Showing Once-Daily Oral Zasocitinib Delivers Higher PASI 100 At 36.5% Vs 13.9% And PASI 90 At 62.5% Vs 34.0% Than Deucravacitinib At Week 16; Under FDA, EMA Review For Plaque Psoriasis
• 13:17 KROS Begins Dosing in Phase II Study With Rinvatercept in DMD
• 12:04 Keros Therapeutics Expects $20M Development Milestone Payment Under Elritercept License Agreement Of With Takeda After Dosing Of First Patient In The ELRiSE MF Clinical Trial
• 18:30 This Cancer Drug Is Already Working. Now Its Nvidia-Backed Maker Is Going Public: Here’s What You Need to Know About Its IPO
• 19:17 Can Sotyktu's Long-Term PsA Data Boost Bristol Myers' Prospects?
• 13:22 5 Undervalued Oncology Stocks Wall Street Is Overlooking (NASDAQ:IBB)
• 13:06 フル・トランスクリプト：武田薬品工業株式会社 第1四半期2026年決算発表電話会議
• 10:03 Best Value Stocks to Buy for September 14th
• 09:28 Best Income Stocks to Buy for September 14th
• 13:40 Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?
• 13:16 Exelixis: 'Hold' On Zanzalintinib Subpopulation Miss And STELLAR-304 H2 2026 Data
• 18:57 Trump Admin To Target Biotechs With Curbs On Drug Pricing? What Investors Should Know
• 16:38 Takeda Secures FDA Approval For First-In-Class Blood Cancer Drug - Takeda Pharmaceutical Co (NYSE:TAK)
• 19:13 Silence Therapeutics: Making Some Recent Noise (NASDAQ:SLN)
• 13:55 Wall Street Analysts Think Takeda Pharmaceutical Co. (TAK) Could Surge 26.41%: Read This Before Placing a Bet
• 13:40 Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?
• 12:29 Best Income Stocks to Buy for August 17th
• 09:51 New Strong Buy Stocks for August 17th